| |
Scientific innovation in ligand targeting has spurred the development of many different types of radiopharmaceuticals (RPs) with a wide range of clinical uses. As those uses have grown, developers of RP products are faced with a regulatory environment that can be a challenge to navigate. We have a roadmap – read our guide for the details. Learn more. Premier Research. Built for Biotech℠
|
|
Today’s Big NewsNov 7, 2023 |
| By James Waldron Vertex Pharmaceuticals may be looking forward to a “milestone-rich period coming up,” but one candidate will no longer be joining the biotech on its journey while another will be delayed into the clinic. |
|
|
|
By James Waldron In another sign that anti-TIGIT antibodies may yet live up to some of the hype, Gilead has unveiled preliminary data showing that its Arcus Biosciences-partnered candidate domvanalimab is effective against gastric cancers in combo with Arcus’ anti-PD-1 drug. |
By James Waldron Sometimes even an apparently successful clinical trial may not be able to save your asset—or your stock price—once you dig into the numbers. |
Sponsored by Resilience US, Inc. Digital twins can help biomanufacturing organizations spot and avoid failures that lead to costly delays. Explore this article to find out how. |
By Max Bayer Pfizer has handed off an AAV capsid aimed at a rare neurological disease target to AstraZeneca’s rare disease arm Alexion as part of a larger, previously announced bundle deal. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Max Bayer Akeso’s bispecific antibody improved overall survival in first-line patients with severe gastric cancer or gastroesophageal junction adenocarcinoma in a phase 3 trial, acing the primary endpoint. |
By Annalee Armstrong Imbria Pharmaceuticals’ heart failure medicine met the safety and tolerability goals in a phase 2 trial but also improved results on a cardiopulmonary exercise test, with patients reporting other improvements in their conditions as well. |
By Helen Floersh The company reported that whole-genome sequence data from thousands of people pointed to 25 gene variants that predispose individuals to developing clonal hematopoiesis, and that a long-reported link between the condition and cardiovascular disease can be largely explained by smoking. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Zoey Becker The company says its launch preparations are "on track" ahead of the FDA's Dec. 8 decision deadline for exa-cel in sickle cell disease. If all goes as planned, Vertex will soon be able to send patients on their lengthy road to treatment. |
By Conor Hale Philips aims to link AI assistance with its Lumify hand-held probe to allow midwives who may have less experience to perform pregnancy checkups. |
By Fraiser Kansteiner There might just be a silver lining for Johnson & Jonhson in the FDA's recent approval of Amgen’s Stelara biosimilar. That’s because the coming entry of a cheaper copycat presents J&J with an opportunity to elude Medicare price negotiations outlined in the Inflation Reduction Act. |
By Heather Landi With continued strong revenue growth, Hims & Hers expects to be profitable by the first half of 2024. The digital health and wellness company boosted its revenue outlook for the year and announced a new AI-powered service to personalize treatments. |
By Ben Adams In October's top 10 drug ad spending list, AbbVie once again leads the charts with its immunology drug Skyrizi, as overall spending on the top 10 drug ads jumped to a near record high for the year. |
Fierce podcastsDon’t miss an episode |
| While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. |
|
|---|
|
|
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
